Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population

International Journal of Clinical Practice

Volumn 67, Issue 1, 2013, Pages 81-88

  Martinez Hervas, S ^a,b   Real, J T ^a,b,c   Priego, M A ^a,c   Carratala A ^a   Sniderman, A D ^d   Carmena, R ^a,b,c   Ascaso, J F ^a,b,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SOUTHERN EUROPE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; REFERENCE VALUES; SPAIN; TRIGLYCERIDES; YOUNG ADULT;

EID: 84871417162     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.02998.x     Document Type: Article

References (44)

1. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106: 3143-421.
2. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35 (Suppl. 1): S11-63.
3. Catapano AL, Reiner Z, De Backer G, et al., ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217 (Suppl. 1): S1-44.
4. Contois JH, Warnick GR, Sniderman AD,. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. J Clin Lipidol 2011; 5: 264-72.
5. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
6. Tighe DA, Ockene IS, Reed G, Nicolosi R,. Calculated low density lipoprotein cholesterol levels frequently underestimate directly measured low density lipoprotein cholesterol determinations in patients with serum triglyceride levels < or =4.52 mmol/l: an analysis comparing the LipiDirect magnetic LDL assay with the Friedewald calculation. Clin Chim Acta 2006; 365: 236-42.
7. Olofsson SO, Boren J,. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 2005; 258: 395-410.
8. Packard CJ, Demant T, Stewart JP, et al., Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 2000; 41: 305-18.
9. Barter PJ, Ballantyne CM, Carmena R, et al., Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006; 259: 247-58.
10. Benderly M, Boyko V, Goldbourt U,. Apolipoproteins and long-term prognosis in coronary heart disease patients. Am Heart J 2009; 157: 103-10.
11. Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B,. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003; 91: 1173-7.
12. Genest J, McPherson R, Frohlich J, et al., 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009; 25: 567-79.
13. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC,. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-5.
14. ter Welle HF, Baartscheer T, Fiolet JW,. Influence of free glycerol on enzymic evaluation of triglycerides. Clin Chem 1984; 30: 1102-3.
15. Burstein M, Scholnick HR, Morfin R,. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 11: 583-95.
16. Rosseneu M, Vercaemst R, Steinberg KK, Cooper GR,. Some considerations of methodology and standardization of apolipoprotein B immunoassays. Clin Chem 1983; 29: 427-33.
17. Hirany S, Li D, Jialal I,. A more valid measurement of low-density lipoprotein cholesterol in diabetic patients. Am J Med 1997; 102: 48-53.
18. Rubies-Prat J, Reverter JL, Senti M, et al., Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 1993; 16: 1081-6.
19. Chapman MJ, Ginsberg HN, Amarenco P, et al., Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345-61.
20. Wagner AM, Perez A, Calvo F, Bonet R, Castellvi A, Ordonez J,. Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients. Diabetes Care 1999; 22: 812-7.
21. Despres JP, Lamarche B, Mauriege P, et al., Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7.
22. Real JT, Romero P, Martinez Hervas S, Pedro T, Carmena R, Ascaso JF,. [Role of atherogenic dyslipidemia in the development of metabolic syndrome]. Med Clin (Barc) 2006; 127: 321-4.
23. Sniderman A, Williams K, de Graaf J,. Non-HDL C equals apolipoprotein B: except when it does not!. Curr Opin Lipidol 2010; 21: 518-24.
24. Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J,. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. J Intern Med 2010; 268: 567-77.
25. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB,. Non-highdensity lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112: 3375-83.
26. Jacobson TA,. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. Int J Clin Pract 2011; 65: 82-101.
27. Thompson A, Danesh J,. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006; 259: 481-92.
28. Di Angelantonio E, Sarwar N, Perry P, et al., Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000.
29. Sniderman AD, Williams K, Contois JH, et al., A meta-analysis of low-density lipoprotein cholesterol, nonhigh-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011; 4: 337-45.
30. Benn M,. Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. Atherosclerosis 2009; 206: 17-30.
31. Koivistoinen T, Hutri-Kahonen N, Juonala M, et al., Apolipoprotein B is related to arterial pulse wave velocity in young adults: the Cardiovascular Risk in Young Finns Study. Atherosclerosis 2011; 214: 220-4.
32. Walldius G,. Apolipoprotein B (apoB) more closely related to subclinical atherosclerosis than non-HDL cholesterol and LDL cholesterol. J Intern Med 2010; 268: 549-51.
33. Vaverkova H, Karasek D, Novotny D, et al., Apolipoprotein B versus LDL-cholesterol: association with other risk factors for atherosclerosis. Clin Biochem 2009; 42: 1246-51.
34. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E,. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
35. Lamarche B, Moorjani S, Lupien PJ, et al., Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996; 94: 273-8.
36. Brunzell JD, Davidson M, Furberg CD, et al., Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31: 811-22.
37. Sniderman A, McQueen M, Contois J, Williams K, Furberg CD,. Why is nonhigh-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol 2010; 4: 152-5.
38. Cui Y, Blumenthal RS, Flaws JA, et al., Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161: 1413-9.
39. Boden WE, Probstfield JL, Anderson T, et al., Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
40. Ramjee V, Sperling LS, Jacobson TA,. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol 2011; 58: 457-63.
41. Sniderman A, Couture P, de Graaf J,. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol 2010; 6: 335-46.
42. Davidson MH, Ballantyne CM, Jacobson TA, et al., Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol 2011; 5: 338-67.
43. Parish S, Peto R, Palmer A, et al., The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009; 30: 2137-46.
44. Contois JH, McConnell JP, Sethi AA, et al., Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009; 55: 407-19.